tiprankstipranks
Intellia Therapeutics (NTLA)
NASDAQ:NTLA

Intellia Therapeutics Stock Forecast & Price Targets

1,782 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Strong Buy
15Ratings
12 Buy
3 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

Analyst Price Target on NTLA

Average Price Target

$107.15
▲(66.98% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $107.15 with a high forecast of $163.00 and a low forecast of $54.00. The average price target represents a 66.98% change from the last price of $64.17.
Highest Price Target$163.00Average Price Target$107.15Lowest Price Target$54.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
SVB Securities
$152.00
Buy
136.87%
Upside
Reiterated
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush
$68.00
Hold
5.97%
Upside
Reiterated
Intellia Therapeutics (NTLA) PT Raised to $68 at WedbushWedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $68.00 (from $55.00) while maintaining a Neutral rating.
William Blair
Buy
Assigned
Intellia Therapeutics (NTLA) Receives a Buy from William Blair
Bank of America Securities
$70.00
Buy
9.09%
Upside
Initiated
Intellia Therapeutics initiated with a Buy at BofAIntellia Therapeutics initiated with a Buy at BofA
Evercore ISI
$75.00
Buy
16.88%
Upside
Reiterated
Evercore ISI Thinks Intellia Therapeutics' Stock is Going to Recover
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PRVAPrivia Health Group
RXDXPrometheus Biosciences
ROIVRoivant Sciences
ABCLAbCellera Biologics
NRIXNurix Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FAQ

What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is $107.15.
    What is NTLA’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 66.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis